Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Disclaimer (1/2)
This Presentation has been prepared and issued by and is the sole responsibility of Sandoz Group AG ("Sandoz")
and is being furnished to each party to whom it is delivered (each a "Recipient") solely for its own information and
in connection with the spin-off of Sandoz from Novartis AG ("Novartis"). For the purposes of this notice, this
Presentation includes this document, its contents or any part of it and any related video or oral Presentation, any
question or answer session and any written or oral material discussed or distributed during the Presentation
meeting (the "Presentation").
There is no issue, public offering or other placement of shares of Sandoz in connection with this Presentation. This
Presentation does not constitute or form part of, and should not be construed as any offer or invitation or recommendation
to purchase, otherwise acquire, subscribe for, sell, otherwise dispose of or issue, or as a solicitation by or on behalf of
Sandoz or Novartis of any offer to purchase, otherwise acquire, sell, otherwise dispose of, issue, or subscribe for, any
shares in Sandoz or any other Sandoz or Novartis securities in any jurisdiction. The release, publication or distribution of
this Presentation in certain jurisdictions may be restricted by law and therefore persons into whose possession this
Presentation comes should inform themselves about and observe any such restrictions in relation to the shares of Sandoz
or this Presentation, including those in the paragraphs that follow. No action has been taken or will be taken to permit the
possession, issue or distribution of this Presentation in any country or jurisdiction where action for that purpose is required
or doing so is restricted by law. Failure to comply with these restrictions may constitute a violation of the securities laws or
regulations of such jurisdictions. To the fullest extent permitted by law, Sandoz and its respective representatives, affiliates
and advisors disclaim any responsibility or liability for the violation of such requirements by any person. The information
contained in this Presentation has been provided by Sandoz and by the other sources identified in this Presentation, has
not been verified independently and is provided for information purposes only.
THIS PRESENTATION IS NOT A PROSPECTUS WITHIN THE MEANING OF THE SWISS FINANCIAL SERVICES ACT
("FINSA"). INVESTORS SHOULD MAKE THEIR INVESTMENT DECISIONS SOLELY BASED ON THE LISTING
PROSPECTUS WHICH IS EXPECTED TO BE PUBLISHED AND WHICH WILL BE SUBMITTED TO SIX EXCHANGE
REGULATION LTD IN ITS CAPACITY AS SWISS REVIEW BODY PURSUANT TO ARTICLE 52 FINSA.
In making an investment decision (e.g., to hold the shares of Sandoz or American Depositary Receipts with shares of
Sandoz underlying them ("ADRS") received in connection with the spin-off, to sell such shares or ADRs so received
or to purchase such shares or ADRs after the planned listing of the Sandoz shares), investors must rely on their own
investigation of Sandoz, including the merits and risks involved. Sandoz does not make any representation to any investor
regarding the legality of an investment in the Sandoz shares by such investor. Each investor should consult with his or
her own advisors as to the legal, tax, business, financial and related aspects of an investment in the Sandoz shares.
This Presentation does not constitute investment, legal, accounting, regulatory, taxation or other advice.
The information contained in this Presentation has been prepared as of the date of this Presentation. Neither the delivery
of this Presentation nor any sale made hereunder shall, under any circumstances, create any implication that there has
been no change in the affairs of Sandoz since the date hereof or that the information contained herein is correct as of any
time after the date hereof. It can also not be ruled out that omissions or errors might have occurred. Sandoz disclaims any
obligation to update or revise any information, in particular forward-looking statements, to reflect future events or
developments, except as may be required by law. Sandoz and any of its respective affiliates, personally liable directors,
officers, employees, advisors or agents, accept no responsibility and have no liability to you or to any third parties, for the
accuracy, fairness, timeliness, continued availability or completeness of any data or calculations contained and/or referred
to in this Presentation or any other information relating to Sandoz, whether written, oral or in a visual or electronic form,
and howsoever transmitted or made available.
Neither this Presentation, the listing, the separation, nor the spin-off constitutes or forms part of, and should not be
construed as, any offer or invitation or recommendation to purchase, otherwise acquire, subscribe for, sell, otherwise
dispose of or issue, or as a solicitation of any offer to purchase, otherwise acquire, sell, otherwise dispose of, issue, or
subscribe for, any security, including any shares in Sandoz or any other Sandoz or Novartis securities, in any jurisdiction
where it would be unlawful to do so. Investors should familiarize themselves with the prospectus for more details on
applicable restrictions.
This Presentation does not constitute an offer to sell, or a solicitation by or on behalf of Sandoz or Novartis of an offer to
purchase or sell, shares, ADRs or any securities of Sandoz or Novartis in any jurisdiction.
The issuance of shares and the ADRs has not been and will not be registered under the U.S. Securities Act of 1933, as
amended, or with any securities regulatory authority of any state or other jurisdiction in the United States. Neither the U.S.
Securities and Exchange Commission nor any U.S. state securities commission has approved or disapproved the Sandoz
shares or ADRs or passed comment or opinion upon the accuracy of this Presentation. Any representation to the contrary
is a criminal offense in the United States.
2
Management Presentation
SANDOZView entire presentation